RU2015137671A - Профилактическое или терапевтическое лекарственное средство для лечения запора - Google Patents

Профилактическое или терапевтическое лекарственное средство для лечения запора Download PDF

Info

Publication number
RU2015137671A
RU2015137671A RU2015137671A RU2015137671A RU2015137671A RU 2015137671 A RU2015137671 A RU 2015137671A RU 2015137671 A RU2015137671 A RU 2015137671A RU 2015137671 A RU2015137671 A RU 2015137671A RU 2015137671 A RU2015137671 A RU 2015137671A
Authority
RU
Russia
Prior art keywords
constipation
treatment
preventive
therapeutic medicine
compound
Prior art date
Application number
RU2015137671A
Other languages
English (en)
Other versions
RU2648467C2 (ru
Inventor
Дайсуке ЯМАМОТО
Фусайо ИО
Кодзи ЯМАМОТО
Original Assignee
Тайсо Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайсо Фармасьютикал Ко., Лтд. filed Critical Тайсо Фармасьютикал Ко., Лтд.
Publication of RU2015137671A publication Critical patent/RU2015137671A/ru
Application granted granted Critical
Publication of RU2648467C2 publication Critical patent/RU2648467C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (4)

1. Профилактическое или терапевтическое лекарственное средство для лечения запоров, включающее соединение, ингибирующее SGLT1, или его фармацевтически приемлемую соль в качестве активного ингредиента.
2. Профилактическое или терапевтическое лекарственное средство для лечения запоров по п. 1, где соединением, ингибирующим SGLT1, является соединение 4-изопропилфенилглюцитола, представленное следующей формулой (I).
[Формула I]
Figure 00000001
RU2015137671A 2013-02-04 2014-02-03 Профилактическое или терапевтическое лекарственное средство для лечения запора RU2648467C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013019754 2013-02-04
JP2013-019754 2013-02-04
PCT/JP2014/052465 WO2014119787A1 (ja) 2013-02-04 2014-02-03 便秘症の予防又は治療薬

Publications (2)

Publication Number Publication Date
RU2015137671A true RU2015137671A (ru) 2017-03-10
RU2648467C2 RU2648467C2 (ru) 2018-03-26

Family

ID=51262485

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015137671A RU2648467C2 (ru) 2013-02-04 2014-02-03 Профилактическое или терапевтическое лекарственное средство для лечения запора

Country Status (17)

Country Link
US (1) US10022389B2 (ru)
EP (1) EP2952206B1 (ru)
JP (1) JP5807767B2 (ru)
KR (1) KR102078433B1 (ru)
CN (1) CN104955481B (ru)
AU (1) AU2014213251B2 (ru)
BR (1) BR112015017541A2 (ru)
CA (1) CA2899834C (ru)
ES (1) ES2694110T3 (ru)
IL (1) IL240192A (ru)
MX (1) MX346453B (ru)
MY (1) MY176162A (ru)
PH (1) PH12015501696A1 (ru)
RU (1) RU2648467C2 (ru)
SG (2) SG10201700267PA (ru)
TW (1) TWI659739B (ru)
WO (1) WO2014119787A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019142774A (ja) * 2016-06-20 2019-08-29 大正製薬株式会社 腸内環境改善剤
JP7669493B2 (ja) * 2021-07-30 2025-04-28 セトラスホールディングス株式会社 酸化マグネシウムを含有する小児慢性機能性便秘症治療用医薬組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2830424C3 (de) * 1978-07-11 1982-04-15 Bayer Ag, 5090 Leverkusen alpha -Glucosidase-Inhibitoren
US5651988A (en) 1995-08-18 1997-07-29 Xyrofin Oy Combination osmotic and bulk forming laxatives
US7375087B2 (en) 2002-08-08 2008-05-20 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
US20060035844A1 (en) 2002-12-04 2006-02-16 Fumiaki Ito Preventive or remedy for diseases caused by hyperglycemia
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
TW200812995A (en) 2006-05-19 2008-03-16 Taisho Pharmaceutical Co Ltd C-phenyl glycitol compound
CA2655937A1 (en) 2006-06-29 2008-01-03 Taisho Pharmaceutical Co., Ltd. C-phenyl 1-thioglucitol compound
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008072726A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. １－フェニル １－チオ－ｄ－グルシト－ル誘導体
GB2447067A (en) * 2007-02-20 2008-09-03 Branko R Babic Alteration of osmotic gradients by polyhydroxy compounds
WO2009084531A1 (ja) 2007-12-27 2009-07-09 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体のモノセバシン酸塩
ES2385185T3 (es) 2008-04-16 2012-07-19 Kissei Pharmaceutical Co., Ltd. Hemifumarato de un derivado de pirazol
CA2752212C (en) * 2009-02-23 2016-08-16 Taisho Pharmaceutical Co., Ltd. 4-isopropylphenyl glucitol compounds as sglt1 inhibitors
JP2013224263A (ja) 2010-08-19 2013-10-31 Taisho Pharmaceutical Co Ltd ４−イソプロピルフェニルグルシトール化合物
US9161945B2 (en) 2010-08-20 2015-10-20 Taisho Pharmaceutical Co., Ltd. 4-isopropyl-6-methoxyphenyl glucitol compound
CA2807755A1 (en) 2010-08-20 2012-02-23 Taisho Pharmaceutical Co., Ltd. Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
EP2848254B1 (en) 2012-05-07 2016-08-03 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes
EP2925735B1 (en) * 2012-11-20 2019-03-13 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1

Also Published As

Publication number Publication date
IL240192A (en) 2017-03-30
PH12015501696B1 (en) 2015-10-12
ES2694110T3 (es) 2018-12-18
US20150374735A1 (en) 2015-12-31
EP2952206A1 (en) 2015-12-09
JP5807767B2 (ja) 2015-11-10
PH12015501696A1 (en) 2015-10-12
CA2899834C (en) 2020-09-01
RU2648467C2 (ru) 2018-03-26
AU2014213251B2 (en) 2017-07-20
SG10201700267PA (en) 2017-02-27
TW201517903A (zh) 2015-05-16
KR102078433B1 (ko) 2020-02-17
HK1211479A1 (en) 2016-05-27
JPWO2014119787A1 (ja) 2017-01-26
SG11201506047PA (en) 2015-09-29
AU2014213251A1 (en) 2015-08-27
CN104955481B (zh) 2017-10-24
WO2014119787A1 (ja) 2014-08-07
IL240192A0 (en) 2015-09-24
KR20150112949A (ko) 2015-10-07
BR112015017541A2 (pt) 2017-07-11
EP2952206B1 (en) 2018-10-24
EP2952206A4 (en) 2016-06-15
CA2899834A1 (en) 2014-08-07
US10022389B2 (en) 2018-07-17
CN104955481A (zh) 2015-09-30
TWI659739B (zh) 2019-05-21
MX346453B (es) 2017-03-17
MX2015010029A (es) 2015-10-30
MY176162A (en) 2020-07-24

Similar Documents

Publication Publication Date Title
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EP4643945A3 (en) Neuroactive steroids and methods of use thereof
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
NZ607580A (en) N-heteroaryl compounds
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
MX364400B (es) Compuestos de tetraciclina.
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
ME02405B (me) Spojevi pirazola као inhibitori sglt1
PH12016500577B1 (en) Piperazine derivatives and the use thereof as medicament
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes
MY197518A (en) Preventive and/or therapeutic agent of immune disease
MX2014011520A (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
PH12015501696B1 (en) Prophylactic or therapeutic drug for constipation
RU2023125521A (ru) Комбинированная терапия для лечения рака
NZ630795A (en) Crystalline form of vsn16
WO2014024013A8 (en) Pseudouridimycin (pum) and its derivates
RU2013127881A (ru) Применение фармацевтической композиции на основе соли четвертичного фосфония и замещенного динитробензофуроксана для лечения пироплазмоза у собак и способ лечения
TH129239A (th) ไตรอะซีน-ออกซาไดอะโซล (Triazine-Oxadiazoles)